Genelux Corporation has announced new compensation terms for its recently appointed Chief Medical Officer, Dr. Jason Litten. Effective January 2, 2026, Dr. Litten will receive an annual base salary of $475,000 and will be eligible for a discretionary annual bonus of up to 40% of his base salary, contingent on performance goals set by the Board of Directors. He has also been granted an option to purchase 275,000 shares of the company’s common stock, vesting over four years, with accelerated vesting in the event of a change in control. In case of involuntary termination, Dr. Litten will be eligible for severance benefits, including up to 12 months of salary and COBRA health insurance, with enhanced terms if termination occurs around a change in control.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-000115), on January 02, 2026, and is solely responsible for the information contained therein.